Akers Expands U.S. Sales Efforts With Key Leadership Additions
January 20 2015 - 7:00AM
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company"),
a leading designer and manufacturer of rapid diagnostic screening
and testing products, announces the recruitment and deployment of a
full-time, pan-U.S. sales and marketing team under the direction of
the newly appointed Executive Vice President, Sales and Marketing,
John C. Cheneval.
Mr. Cheneval is a leader in the field of commercializing
diagnostic products within the healthcare sector. He has 25 years
of high level industry experience including senior roles within
Johnson & Johnson, Novartis Molecular Diagnostics and Genoptix
Medical Labs. Mr. Cheneval has a successful track record of
commercializing diagnostic tests and launching novel assays into
the market. He has been responsible for the launch and management
of several hundred million dollars of diagnostic product sales.
The Company also announces the appointment of Christopher Ellis
as Vice President, Global Marketing. Mr. Ellis most recently led
provider marketing for (and was one of six founding members of)
Vree Health, LLC, a wholly-owned subsidiary of Merck, one of the
largest pharmaceutical companies in the world. Prior to Vree
Health, Mr. Ellis spent 12 years in various positions of increasing
responsibility within sales and marketing at Merck.
The Company has recruited multiple experienced full-time medical
product sales representatives in order to focus extensively on
growing U.S. sales of the Company's flagship PIFA Heparin/PF4 Rapid
Assay products. Our full-time sales representatives are based in
strategic locations across the U.S. including San Diego, New York
City, Dallas, St. Louis and Orlando.
"The injection of capital from 2014's NASDAQ listing, coupled
with growing revenues from product sales, is enabling Akers to put
significant weight behind driving the internal sales capacity of
our current core products which test for the condition known as
heparin induced thrombocytopenia ("HIT")," said Raymond F. Akers,
Jr. PhD, Co-founder and Executive Chairman of the Board.
"Domestically, the Company is now in the position of being able
to activate a comprehensive, multi-layered sales strategy which
encompasses direct sales, telesales and distribution. Akers has
partnered with Typenex for telesales and has established
distribution with blue chip medical product distributors including
Cardinal, Medline and Fisher. Such partners may in the future be
involved in selling additional products from the Company's growing
pipeline of tests in various stages of development," continued Dr.
Akers.
"The sales team which has been deployed into the field will
focus on sales of the Company's current core product which has the
capacity to generate substantial annual cost savings to hospitals
through more efficient diagnosis of the condition it tests for,"
said John C. Cheneval, Executive Vice President, Sales and
Marketing.
"Evidence of demand for Akers' test is demonstrated by the
hospitals already using it," added Mr. Cheneval. "But right now we
are barely scratching the surface of its potential market. Putting
top quality sales representatives in the field is key to achieving
the kind of penetration this test has the capacity to deliver."
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid,
point of care screening and testing products designed to bring
healthcare information both rapidly and directly to the consumer or
healthcare provider. The Company has advanced the science of
diagnostics while responding to major shifts in healthcare through
the development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical products distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found on our website at www.akersbiosciences.com. Follow us on
Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking
Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
CONTACT: For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
RedChip Companies, Inc. (US Investor Relations)
Jon Cunningham
Tel. +1 407 644 4256 x107
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel: +44 (0)20 7220 0500
Vigo Communications (UK Investor Relations)
Ben Simons / Alexandra Roper
Tel. +44 (0)20 7016 9570
Email. akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024